74 
In fact. Dr. Rosenblith, who is sitting right next to you is the chair- 
man of the group at MIT that will, in fact, review such procedures, such 
experimental work at MIT. There are equivalent groups at Harvard, at 
Stanford, and I think at most major institutions where such work is likely 
to be undertaken, and in fact in some cases that review is going down to the 
departmental level, because in our own department at Stanford, we have a 
departmental review of any such procedures and any such experiments. 
DR. ROSENBLITH: One little footnote. I am not the chairman; I 
appointed the chairman. 
(Laughter. ) 
DR. FREDRICKSON: Dr. Berg, while you are there, Mrs. Peterson also 
asked another question which no one has answered, and that is under what 
groundrules are we proceeding today in recombinant DNA research? 
DR. BERG: Well, I think they differ in different places. As I under- 
stand it, the NIH has already in fact an inhouse review committee which has 
been acting on experimental protocols generated here. I think by and large 
most people, at least in this country, are using the Asilomar guidelines, 
as crude and as vague as they were, until the permanently considered ones 
will be promulgated. 
In other countries there are a variety of conditions. In Great Britain 
it is more stringently proscribed than it is here, at the moment; but in 
various countries, and I think there is a summary of these in your book, 
and in some cases it says there is absolutely no review and constraint. In 
Australia there is a committee which is reviewing proposal by proposal, and 
approving or disapproving them to carry on this work. 
DR. FREDRICKSON: Dr. Hudson? 
DR. HUDSON: We have been told that there are 27 designated high- 
containment centers with facilities available, with nine others under way. 
I wonder if there will be certain types of grants only provided for these 
27 plus the other possible nine, and will this produce some types of pro- 
blems for other areas where there might be competent personnel but without 
facilities of a high-containment nature? 
DR. FREDRICKSON: Dr. Stetten? 
DR. STETTEN: The committee early considered the mandate from the 
Director of NIH as to whether specific support was needed at this time for 
the construction of additional high-containment facilities. The Director 
of the Cancer Institute had indicated that he believed that he could pro- 
vide funds for such if these were needed. 
[215] 
